Glycoconjugate vaccines for use in immune-compromised populations
OwnerAli I. Fattom, Robert B. Nasoinventors
Life of this patent
Estimating the term…
Abstract
Staphylococcal and Enterrococcal glycoconjugate vaccines are disclosed for use in preventing or treating bacterial infection in an immune-compromised individual. Such vaccines contain an immunocarrier and a conjugate of a polysaccharide or glycopeptide surface antigen from a clinically-significant bacterial strain. The vaccines can be used for active protection in immune-compromised individuals who are to be subjected to conditions that place them at immediate risk of developing a bacterial infection, as would be case in the context of a catheterization or a surgical procedure.
Claims19
A method of protecting an immune-compromised human from at least one of Staphylococcal and Enterococcal bacterial infection, comprising administering a vaccine comprising a glycoconjugate of a polysaccharide or glycopeptide bacterial surface antigen and an immunocarrier to an immune-compromised human, wherein said vaccine comprises:
- (a) glycoconjugates of both Type 5 and Type 8 polysaccharide antigens of S. aureus,
- (b) a glycoconjugate of a negatively-charged Staphylococcal polysaccharide antigen that comprises β-linked hexosamine as a major carbohydrate component and contains no O-acetyl groups,
- (c) a glycoconjugate of Staphylococcal glycopeptide antigen that comprises amino acids and a N-acetylated hexosamine in an α configuration, that contains no O-acetyl groups, and that contains no hexose,
- (d) a glycoconjugate of an acidic Staphylococcal polysaccharide antigen that is obtained from an isolate of S. epidermidis that agglutinates antisera to ATCC 55254,
- (e) a glycoconjugate of an E. faecalis antigen that comprises 2-acetamido-2-deoxy-glucose and rhamnose in a 1:2 molar ratio,
- (f) a glycoconjugate of an E. faecalis antigen that comprises a trisaccharide repeat which comprises a 6-deoxy sugar,
- (g) a glycoconjugate of an E. faecium antigen that comprises 2-acetamido-2-deoxy-galactose and galactose in a 2:1 molar ratio,
- (h) a glycoconjugate of an E. faecium antigen that reacts with antibodies to ATCC 202016, or
- (i) a glycoconjugate of an E. faecium antigen that reacts with antibodies to ATCC 202017.
Dependencies are inferred from the claim text.